CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Bayer Intellectual Property GmbH v. InvaGen Pharmaceuticals, Inc.

1:16-cv-00064

Overview

Case Number 1:16-cv-00064
Filing Date 2016-02-04
Status Terminated
Termination Date 2018-09-10
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

InvaGen Pharmaceuticals, Inc. Operating Company

Represented By

4 Attorneys Listed

Salvatore Guerriero

Email: sguerriero@crbcp.com

Robert S. Silver

Email: rsilver@langergrogan.com

Pei-Ru Wey

Email: Peiru.Wey@offitkurman.com

R. Touhey Myer

Kratz & Barry LLP

Tel: +1 (302) 527-8378

800 N. West Street, Wilmington, DE 19801

Plaintiff

Janssen Pharmaceuticals, Inc. Operating Company

Represented By

3 Attorneys Listed

Rodger Dallery Smith , II

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9205

1201 North Market Street, P.O. Box 1347

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Bayer Pharma AG NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Rodger Dallery Smith , II

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9205

1201 North Market Street, P.O. Box 1347

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Bayer Intellectual Property GmbH Operating Company

Represented By

3 Attorneys Listed

Rodger Dallery Smith , II

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9205

1201 North Market Street, P.O. Box 1347

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 1 proceeding
🏛️
USPTO PTAB Trials 3 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): 🇩🇪 Germany 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (4 found):
PTAB: 3 U.S. Courts: 1
USPTO PTAB Trial 2016-10-07
IPR2017-00043

Mylan Pharmaceuticals Inc. et al. v. Bayer Intellectual Property GmbH et al.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2016-10-07
IPR2017-00042

Mylan Pharmaceuticals Inc. et al. v. Bayer Intellectual Property GmbH et al.

U.S. Continuation Sibling (7585860)
Status: Terminated
USPTO PTAB Trial 2016-10-07
IPR2017-00041

Mylan Pharmaceuticals Inc et al. v. Bayer Intellectual Property GmbH et al.

U.S. Continuation Sibling (7157456)
Status: Terminated
U.S. District Court 2016-07-25
1:16-cv-00628

Bayer Intellectual Property GMBH v. Breckenridge Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7157456
Substituted oxazolidinones and their use in the field of blood coagulation
Filed: 2000-12-11
Issued: 2007-01-02
Expired (Term Ended) +1415d PTA
Expires: 2024-10-26
US7585860
Substituted oxazolidinones and their use in the field of blood coagulation
Filed: 2008-02-07
Issued: 2009-09-08
Active (1.2 yrs remaining)
Expires: 2028-02-07
US7592339
Substituted oxazolidinones and their use in the field of blood coagulation
Filed: 2006-07-27
Issued: 2009-09-22
Expired (Term Ended)
Expires: 2026-07-27

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1415 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

1

Dispositive

0

Granted

0

Denied

0

Pending / Review

0

Motions by Category

Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending
SO ORDERED, re (12 in 1:16-cv-00064-SLR, 70 in 1:15-cv-00902-SLR) SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. ( Jo...
Entry #— • 2016-02-11

Docket Entries

(40 total)
Pleading / Complaint

COMPLAINT filed against InvaGen Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1871567.) - filed by Bayer Intellectual Property GmbH, Janssen Pharmaceuticals, Inc., Bayer Pharma AG. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(sec) (Entered: 02/04/2016)

Entry #1 • 2016-02-04
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sec) (Entered: 02/04/2016)

Entry #2 • 2016-02-04
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: SEE ANDA Date of Expiration of Patent: SEE ANDA.Thirty Month Stay Deadline: 1/1/2019. (sec) (Entered: 02/04/2016)

Entry #3 • 2016-02-04
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,157,456 B2; 7,585,860 B2; 7,592,339 B2;. (sec) (Entered: 02/04/2016)

Entry #4 • 2016-02-04
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GmbH, Bayer Pharma AG filed by Bayer Intellectual Property GmbH, Bayer Pharma AG. (sec) (Entered: 02/04/2016)

Entry #5 • 2016-02-04
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc